New targets for non-small-cell lung cancer therapy

Abstract

Lung cancer remains the leading cause of malignancy-related deaths in the USA, regardless of advances in therapeutic agents. Non-small-cell lung cancer demonstrates great molecular heterogeneity in which several pathways are simultaneously active leading to tumorigenesis. Novel agents targeting specific pathways associated with apoptosis, cell proliferation, angiogenesis and other mechanisms have emerged as a separate and unique therapeutic class delivering promising results in a vast number of malignancies. This innovative class of agents has been studied in advanced-stage non-small-cell lung cancer and, although some agents have demonstrated a clinical benefit, the overall course of the disease remains relatively unchanged, still holding a poor overall prognosis. Most of these agents have been shown to be 'cytostatic', inducing more stable disease rather than objective responses. Thus, the entrance of these novel agents into our drug armamentarium seems to be more attractive in combination with conventional chemotherapy agents based on additive or synergistic response seen with this combined approach. Herein, we review the most relevant clinical data using these novel targeted agents either alone or in combination with chemotherapy in non-small-cell lung cancer.

Dexamethasone Disrupts Cytoskeleton Organization and Migration of T47D Human Breast Cancer Cells by Modulating the AKT/mTOR/RhoA Pathway

“…breast cancers (Paplomata et al, 2014), non-small-cell lung cancers (Alvarez et al, 2007) and colorectal cancers (Pandurangan, 2013). Therefore, targeted drugs of AKT/mTOR pathway might be helpful for treatment of cancers, especially leading to cell apoptosis (Lou et al, 2014;Sui et al, 2014;Wang et al, 2014).…”

Benzo[e]pyridoindoles, novel inhibitors of the Aurora kinases

“…48 h later the are available. 29 With this in mind, we have further studied the in vivo effect of C1 on mice bearing H358 tumors. Repetitive injections of C1 were well tolerated by the animals and affected tumor growth at least for one and a half month.…”

FTY720 for cancer therapy (Review)

“…Once activated, mTOR triggers the phosphorylation of the downstream target p70S6K1, enhances the transcription of certain mRNAs, and increases the expression of proteins associated with proliferation (53)(54)(55). It has been reported that the PI3K/Akt/mTOR signaling pathway is overactivated in several types of cancer, such as non-small cell lung cancer (56,57), breast cancer (58), colorectal cancer (59) and cholangiocarcinoma (60). Therefore, some experimental cancer drugs aim to inhibit the signaling sequence at some point (61)(62)(63).…”